Abionyx Pharma reports a net loss of 3.52 million euros for 2023, compared with a deficit of 4.21 million the previous year, as well as a 20% reduction in its operating loss to 3.4 million on sales of.
On Thursday, Toulouse-based biotech Abionyx Pharma welcomed the failure of a Phase 3 trial conducted by CSL Behring, a setback which, in its view, validates its recent strategic repositioning.The.
Ex-Celgene CEO takes the top job at TORL—Chutes & Ladders fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Abionyx Pharma announces the appointment of Rob Scott as Chief Medical Officer and Head of R&D, effective immediately, to bring to the biotech company his extensive experience in clinical and.
Abionyx Pharma gains 3% after announcing the successful completion of a third batch for the GMP industrial bioproduction of CER-001 using its new innovative and robust industrial process . The.